Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.

Literature DB >> 21028869

Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.

Sisi Wang¹, Hongyong Zhang, Michael Malfatti, Ralph de Vere White, Primo N Lara, Kenneth Turteltaub, Paul Henderson, Chong-xian Pan.

Abstract

We are developing a method to identify cellular resistance to carboplatin by using accelerator mass spectrometry to measure carboplatin-DNA adducts formed from drug microdoses (∼1/100th the therapeutic dose). Such an approach would be particularly useful if it is still valid in combination chemotherapy. We examined whether the addition of gemcitabine, another chemotherapeutic drug, could influence carboplatin-DNA adduct levels. There were no substantial differences in the levels of carboplatin-DNA adducts in cells upon exposure to the carboplatin/gemcitabine combination at various doses and schedules. These data demonstrate that microdosing is feasible for the characterization of carboplatin resistance when given in combination with gemcitabine.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 21028869 PMCID： PMC2987236 DOI： 10.1021/tx1003547

Source DB: PubMed Journal: Chem Res Toxicol ISSN： 0893-228X Impact factor: 3.739

26 in total

1. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy.

Authors: P J van de Vaart; J Belderbos; D de Jong; K C Sneeuw; D Majoor; H Bartelink; A C Begg
Journal: Int J Cancer Date: 2000-03-20 Impact factor: 7.396

2. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.

Authors: L Y Yang; L Li; H Jiang; Y Shen; W Plunkett
Journal: Clin Cancer Res Date: 2000-03 Impact factor: 12.531

3. DNA isolation and sample preparation for quantification of adduct levels by accelerator mass spectrometry.

Authors: Karen H Dingley; Esther A Ubick; John S Vogel; Kurt W Haack
Journal: Methods Mol Biol Date: 2005

4. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.

Authors: Sang Soo Hah; Kristen M Stivers; Ralph W de Vere White; Paul T Henderson
Journal: Chem Res Toxicol Date: 2006-05 Impact factor: 3.739

5. Human microdosing for the prediction of patient response.

Authors: Paul T Henderson; Chong-Xian Pan
Journal: Bioanalysis Date: 2010-03 Impact factor: 2.681

6. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.

Authors: R A Soo; L Z Wang; L S Tham; W P Yong; M Boyer; H L Lim; H S Lee; M Millward; S Liang; P Beale; S C Lee; B C Goh
Journal: Ann Oncol Date: 2006-05-02 Impact factor: 32.976

Review 7. Mechanisms of resistance to cisplatin and carboplatin.

Authors: David J Stewart
Journal: Crit Rev Oncol Hematol Date: 2007-03-01 Impact factor: 6.312

8. Application of accelerated mass spectrometry (AMS) in DNA adduct quantification and identification.

Authors: K W Turteltaub; K H Dingley
Journal: Toxicol Lett Date: 1998-12-28 Impact factor: 4.372

9. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.

Authors: Shuhei Matsuoka; Bryan A Ballif; Agata Smogorzewska; E Robert McDonald; Kristen E Hurov; Ji Luo; Corey E Bakalarski; Zhenming Zhao; Nicole Solimini; Yaniv Lerenthal; Yosef Shiloh; Steven P Gygi; Stephen J Elledge
Journal: Science Date: 2007-05-25 Impact factor: 47.728

10. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.

Authors: F J P Hoebers; D Pluim; A A M Hart; M Verheij; A J M Balm; G Fons; C R N Rasch; J H M Schellens; L J A Stalpers; H Bartelink; A C Begg
Journal: Cancer Chemother Pharmacol Date: 2007-07-18 Impact factor: 3.333

12 in total

1. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.

Authors: Maike Zimmermann; Si-Si Wang; Hongyong Zhang; Tzu-Yin Lin; Michael Malfatti; Kurt Haack; Ted Ognibene; Hongyuan Yang; Susan Airhart; Kenneth W Turteltaub; George D Cimino; Clifford G Tepper; Alexandra Drakaki; Karim Chamie; Ralph de Vere White; Chong-Xian Pan; Paul T Henderson
Journal: Mol Cancer Ther Date: 2016-11-30 Impact factor: 6.261

Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.

1. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy.

2. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.

3. DNA isolation and sample preparation for quantification of adduct levels by accelerator mass spectrometry.

4. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry.

5. Human microdosing for the prediction of patient response.

6. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.

Review 7. Mechanisms of resistance to cisplatin and carboplatin.

8. Application of accelerated mass spectrometry (AMS) in DNA adduct quantification and identification.

9. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage.

10. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.

1. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.

Review 2. Use of Accelerator Mass Spectrometry in Human Health and Molecular Toxicology.

Review 3. Contemporary management of muscle-invasive bladder cancer.

4. Diagnostic Microdosing Approach to Study Gemcitabine Resistance.

Review 5. Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

6. Correlation of Platinum Cytotoxicity to Drug-DNA Adduct Levels in a Breast Cancer Cell Line Panel.

7. Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy.

8. Progress in personalizing chemotherapy for bladder cancer.

9. DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.

10. Prodrug-based nano-delivery strategy to improve the antitumor ability of carboplatin in vivo and in vitro.